Sir, Cervix cancer is an important female cancer that causes several deaths each year. [1] Luckily, the new vaccine against cervix cancer is already developed and in use. [2] In Thailand, the cervix cancer is also highly prevalent and becomes the leading cause of death among local female, and annual screening is the basic public health policies in Thailand. [3] The introduction of the cervical cancer vaccine in Thailand becomes a new hope for control of the disease. At present, the vaccine is still expensive and its cost becomes a big consideration. Several new reports confirm for the cost-effectiveness of the vaccination of the available vaccines. [4] [5] [6] [7] The vaccine is proven cost-effective regardless commercial types of vaccine. [8] Nevertheless, the additional concern is on the adverse effect of the vaccine. There are only few reports on this issue and extremely few reports regarding the cost and risk of the vaccines. Here, the authors perform the cost and risk analysis of the available cervix cancer vaccines in Thailand -Gardasil and Cervarix. The cost identification is performed. The unit cost at the tertiary hospital in Thailand in USD is used for further analysis. Focusing on the risk, the data from a recent report on the reactogenicity of the vaccines are used for further analysis. [9] The cost-risk analysis is performed, and the result is shown in Table 1 . Conceptually, the good vaccine should have lower cost and lower risk. For cost-risk analysis, it can be seen that Cervarix is slightly cheaper but have significantly more risk. The cost-risk analysis hereby shows that the Gardasil is more favorable.
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